Antithrombotic Management of Acute Myocardial Infarction Patients with New‑Onset Atrial Fibrillation

Immediate Dual‑Therapy Strategy

The American College of Cardiology (ACC) recommends that, within the first 12 months after an acute coronary syndrome, patients with new‑onset atrial fibrillation should receive apixaban plus clopidogrel without aspirin (dual therapy) as the optimal regimen. Class I, Level A recommendation. 1
Aspirin should be stopped immediately when apixaban is initiated. 1
Clopidogrel is the preferred P2Y12 inhibitor to pair with apixaban in this setting. 1
Apixaban should be started at the standard atrial‑fibrillation dose (5 mg twice daily, or 2.5 mg twice daily if dose‑reduction criteria are met). 1

In the ARISTOTLE trial, adding aspirin to apixaban increased major or clinically relevant non‑major bleeding from 1.8 % to 3.4 % per year. This finding supports avoiding aspirin when a DOAC is used. Randomized trial data. 4

The ACC advises continuing apixaban + clopidogrel for up to 12 months after the myocardial infarction. 1
After 12 months, patients should transition to apixaban monotherapy for long‑term stroke prevention. 1
For patients at high bleeding risk and low ischemic risk, a shorter course of clopidogrel (limited to the acute stabilization period) may be considered. 1
For patients at high thrombotic risk and low bleeding risk, clinicians may elect to continue clopidogrel (75 mg daily) beyond 12 months together with apixaban. 1

If a patient is on prasugrel or ticagrelor, the ACC recommends switching to clopidogrel when apixaban is started. 5

Both the European Society of Cardiology (ESC) and the ACC explicitly recommend against prolonged triple therapy (apixaban + aspirin + clopidogrel) after the acute hospitalization period. Class III, Level A recommendation. 4

Antiplatelet therapy cannot replace oral anticoagulation for stroke prevention in atrial fibrillation, as emphasized by ESC guidance. 4
In a comparative analysis, dual antiplatelet therapy (aspirin + clopidogrel) was less effective than warfarin for preventing stroke, with an annual event rate of 5.6 % vs. 3.9 % (P = 0.0003). Randomized trial data. 4

While bleeding‑risk scores are important, the stroke‑prevention benefit of dual therapy generally outweighs bleeding concerns, and anticoagulation should not be withheld solely on the basis of bleeding risk. ACC consensus. 1
The ACC also notes that routine INR monitoring is unnecessary with apixaban, and its pharmacokinetics are more predictable than with vitamin K antagonists. 1